Get started
Author

Hidetoshi Itani

Observed names: H. Itani, Itani, Hidetoshi
ORCID: 0009-0006-2007-4666
Observed ORCID: 0009-0006-2007-4666
OpenAlex ID: A5079653801
Short Hydration in Chemotherapy Containing Cisplatin (>=75 mg/m2) for Patients with Lung Cancer: A Prospective Study
2013 · H. Horinouchi, K. Kubota, et al. · Japanese Journal of Clinical Oncology · 63
Sequential Therapy with Crizotinib and Alectinib in ALK -Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective Study
2016 · Kentaro Ito, Osamu Hataji, et al. · Journal of Thoracic Oncology · 57
PDF
Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer
2020 · Shingo Miyamoto, Koichi Azuma, et al. · JAMA Oncology · 52
PDF
Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors
2021 · Kiyotaka Yoh, Shingo Matsumoto, et al. · Lung Cancer · 24
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al. · Clinical Cancer Research · 18
PDF
Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial
2023 · Reiko Matsuzawa, Masahiro Morise, et al. · EClinicalMedicine · 16
PDF
Prospective exosome‐focused translational research for afatinib study of non‐small cell lung cancer patients expressing EGFR (EXTRA study)
2018 · Yusuke Okuma, Kei Morikawa, et al. · Thoracic Cancer · 14
PDF
Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
2024 · Tadashi Nishimura, Hajime Fujimoto, et al. · Cancer Medicine · 9
Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study
2023 · Saori Takata, Kei Morikawa, et al. · Therapeutic Advances in Medical Oncology · 9
PDF
Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)
2020 · Kei Morikawa, Hisashi Tanaka, et al. · Therapeutic Advances in Medical Oncology · 9
Interstitial pneumonitis associated with dasatinib: two case reports and literature review
2019 · Yuhei Ito, Motoaki Tanigawa, et al. · Respiratory Investigation · 7
Chronic Nodular Pulmonary Aspergillosis in a Patient with Rheumatoid Arthritis
2019 · Yuhei Ito, Motoaki Tanigawa, et al. · Internal Medicine · 7
PDF
Lung abscess caused by Streptococcus pneumoniae serotype 6B
2017 · Yuhei Ito, Hirokazu Toyoshima, et al. · Respiratory Medicine Case Reports · 7
PDF
A Novel Homozygous Variant in GAS2L2 in Two Sisters with Primary Ciliary Dyskinesia
2022 · Guofei Feng, Yifei Xu, et al. · Internal Medicine · 6
PDF
A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 (DATE study).
2022 · Shinji Nakamichi, Kaoru Kubota, et al. · Journal of Clinical Oncology · 5
Pulmonary nocardiosis caused by Nocardia blacklokiae in an immunocompetent patient
2020 · Yuhei Ito, Motoaki Tanigawa, et al. · Respiratory Medicine Case Reports · 5
PDF
Ovarian Metastases from ALK-rearranged Lung Adenocarcinoma: A Case Report and Literature Review
2018 · Hajime Sasano, Akimasa Sekine, et al. · Internal Medicine · 5
PDF
Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy
2022 · Tadashi Nishimura, Hajime Fujimoto, et al. · Cancers · 4
PDF
Inflammatory Biomarkers and Outcome Heterogeneity in Anti-MDA5 Antibody-Associated Interstitial Lung Disease: A Single-Center Consecutive Cohort Study
2026 · Akina Nigi, Keisuke Iwamoto, et al. · Advances in respiratory medicine · 3
PDF
Plasma cell-free DNA methylation profile before afatinib treatment is associated with progression-free and overall survival of patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer
2025 · Mao Fujimoto, Hiroyuki Yasuda, et al. · Clinical Epigenetics · 3
PDF
46P Multi-center, phase II study of docetaxel (DTX) plus ramucirumab (RAM) following platinum-based chemotherapy plus ICIs in patients with NSCLC: SCORPION study
2023 · R. Matsuzawa, M. Morise, et al. · Journal of Thoracic Oncology · 3
PDF
Impact of SWI/SNF complex mutations in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors: Immuno-oncology biomarker study in LC-SCRUM-Japan (LC-SCRUM-IBIS).
2020 · Kiyotaka Yoh, Shingo Matsumoto, et al. · Journal of Clinical Oncology · 3
Clinical, genomic, and pathological features and therapeutic outcomes of non-small cell lung cancer with MTAP-loss.
2025 · Hibiki Udagawa, Shingo Matsumoto, et al. · Journal of Clinical Oncology · 2
P47.14 Study Design of SCORPION: Multi-Center, Phase II Study Following Platinum-Based Chemotherapy Plus ICIs in Patients with NSCLC
2021 · R. Matsuzawa, M. Morise, et al. · Journal of Thoracic Oncology · 2
Large scale clinico-genomic analyses among patients with BRAF-mutated non-small cell lung cancers (NSCLC) identified by nationwide genomic screening project (LC-SCRUM-Japan).
2020 · Tetsuya Sakai, Shingo Matsumoto, et al. · Journal of Clinical Oncology · 2
Works count: 74
Citation count: 346
H-index: 9
I10-index: 7
Year
Topic
Type